{
    "balance": {
        "data": [
            "Consolidated Balance Sheets at September 30, 2019 and December 31, 2018 (unaudited)\t2\tCondensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2019 and 2018 (unaudited)\t3\tCondensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2019 and 2018 (unaudited)\t4\tCondensed Consolidated Statements of Stockholders  Equity for the Three and Nine Months Ended September 30, 2019 and 2018 (unaudited)\t5\tCondensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2019 and 2018 (unaudited)\t7\tNotes to Condensed Consolidated Financial Statements (unaudited)\t8\tItem 2.\tManagement s Discussion and Analysis of Financial Condition and Results of Operations\t28\tItem 3.\tQuantitative and Qualitative Disclosures About Market Risk\t37\tItem 4.\tControls and Procedures\t37\tPART II.\tOTHER INFORMATION\t38\tItem 1.\tLegal Proceedings\t38\tItem 1A.\tRisk Factors\t38\tItem 2.\tUnregistered Sales of Equity Securities and Use of Proceeds\t50\tItem 3.\tDefaults Upon Senior Securities\t50\tItem 4.\tMine Safety Disclosures\t50\tItem 5.\tOther Information\t50\tItem 6.\tExhibits\t50\tSIGNATURES\t54\tWe own or have rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD\t\u00ae\t, GILEAD SCIENCES\t\u00ae\t, AMBISOME\t\u00ae\t, ATRIPLA\t\u00ae\t, BIKTARVY\t\u00ae\t, CAYSTON\t\u00ae\t, COMPLERA\t\u00ae\t, DESCOVY\t\u00ae\t,\tDESCOVY FOR PREP\t\u2122\t,\tEMTRIVA\t\u00ae\t, EPCLUSA\t\u00ae\t, EVIPLERA\t\u00ae\t, GENVOYA\t\u00ae\t, HARVONI\t\u00ae\t, HEPSERA\t\u00ae\t, LETAIRIS\t\u00ae\t, ODEFSEY\t\u00ae\t, RANEXA\t\u00ae\t, SOVALDI\t\u00ae\t, STRIBILD\t\u00ae\t, TRUVADA\t\u00ae\t, TRUVADA FOR PREP\t\u00ae\t, TYBOST\t\u00ae\t, VEMLIDY\t\u00ae\t, VIREAD\t\u00ae\t, VOSEVI\t\u00ae\t, YESCARTA\t\u00ae\tand ZYDELIG\t\u00ae\t. LEXISCAN\t\u00ae\tis a registered trademark of Astellas U.S. LLC. MACUGEN\t\u00ae\tis a registered trademark of Eyetech, Inc. SYMTUZA\t\u00ae\tis a registered trademark of Janssen Sciences Ireland UC. TAMIFLU\t\u00ae\tis a registered trademark of Hoffmann-La Roche Inc. This report also includes other trademarks, service marks and trade names of other companies.\tPART I.\tFINANCIAL INFORMATION\tItem 1.    CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED BALANCE SHEETS\t(unaudited)\t(in millions, except per share amounts)\tSeptember 30, 2019\tDecember 31, 2018\tAssets\tCurrent assets:\tCash and cash equivalents\t$\t9,474\t$\t17,940\tShort-term marketable securities\t13,382\t12,149\tAccounts receivable, net of allowances of $613 and $583, respectively\t3,315\t3,327\tInventories\t882\t814\tPrepaid and other current assets\t1,308\t1,606\tTotal current assets\t28,361\t35,836\tProperty, plant and equipment, net\t4,377\t4,006\tLong-term marketable securities\t2,195\t1,423\tIntangible assets, net\t14,864\t15,738\tGoodwill\t4,117\t4,117\tOther long-term assets\t5,232\t2,555\tTotal assets\t$\t59,146\t$\t63,675\tLiabilities and Stockholders  Equity\tCurrent liabilities:\tAccounts payable\t$\t632\t$\t790\tAccrued government and other rebates\t3,652\t3,928\tOther accrued liabilities\t2,785\t3,139\tCurrent portion of long-term debt and other obligations, net\t2,498\t2,748\tTotal current li",
            "CONSOLIDATED BALANCE SHEETS\t(unaudited)\t(in millions, except per share amounts)\tSeptember 30, 2019\tDecember 31, 2018\tAssets\tCurrent assets:\tCash and cash equivalents\t$\t9,474\t$\t17,940\tShort-term marketable securities\t13,382\t12,149\tAccounts receivable, net of allowances of $613 and $583, respectively\t3,315\t3,327\tInventories\t882\t814\tPrepaid and other current assets\t1,308\t1,606\tTotal current assets\t28,361\t35,836\tProperty, plant and equipment, net\t4,377\t4,006\tLong-term marketable securities\t2,195\t1,423\tIntangible assets, net\t14,864\t15,738\tGoodwill\t4,117\t4,117\tOther long-term assets\t5,232\t2,555\tTotal assets\t$\t59,146\t$\t63,675\tLiabilities and Stockholders  Equity\tCurrent liabilities:\tAccounts payable\t$\t632\t$\t790\tAccrued government and other rebates\t3,652\t3,928\tOther accrued liabilities\t2,785\t3,139\tCurrent portion of long-term debt and other obligations, net\t2,498\t2,748\tTotal current liabilities\t9,567\t10,605\tLong-term debt, net\t22,090\t24,574\tLong-term income taxes payable\t5,852\t5,922\tOther long-term obligations\t901\t1,040\tCommitments and contingencies (Note 11)\tStockholders  equity:\tPreferred stock, par value $0.001 per share; 5 shares authorized; none outstanding\t \t \tCommon stock, par value $0.001 per share; 5,600 shares authorized; 1,266 and 1,282 shares issued and outstanding, respectively\t1\t1\tAdditional paid-in capital\t2,870\t2,282\tAccumulated other comprehensive income\t117\t80\tRetained earnings\t17,616\t19,024\tTotal Gilead stockholders  equity\t20,604\t21,387\tNoncontrolling interest\t132\t147\tTotal stockholders  equity\t20,736\t21,534\tTotal liabilities and stockholders  equity\t$\t59,146\t$\t63,675\tSee accompanying notes.\t2\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS\t(unaudited)\t(in millions, except per share amounts)\tThree Months Ended\tNine Months Ended\tSeptember 30,\tSeptember 30,\t2019\t2018\t2019\t2018\tRevenues:\tProduct sales\t$\t5,516\t$\t5,455\t$\t16,323\t$\t15,996\tRoyalty, contract and other revenues\t88\t141\t247\t336\tTotal revenues\t5,604\t5,596\t16,570\t16,332\tCosts and expenses:\tCost of goods sold\t1,035\t1,086\t2,992\t3,283\tResearch and development expenses\t4,990\t939\t7,207\t3,068\tSelling, general and administrative expenses\t1,052\t948\t3,177\t2,925\tTotal costs and expenses\t7,077\t2,973\t13,376\t9,276\tIncome (loss) from operations\t(\t1,473\t)\t2,623\t3,194\t7,056\tInterest expense\t(\t250\t)\t(\t264\t)\t(\t752\t)\t(\t820\t)\tOther income (expense), net\t222\t305\t817\t547\tIncome (loss) before provision (benefit) for income taxes\t(\t1,501\t)\t2,664\t3,259\t6,783\tProvision (benefit) for income taxes\t(\t333\t)\t565\t584\t1,326\tNet income (loss)\t(\t1,168\t)\t2,099\t2,675\t5,457\tNet income (loss) attributable to noncontrolling interest\t(\t3\t)\t2\t(\t15\t)\t5\tNet income (loss) attributable to Gilead\t$\t(\t1,165\t)\t$\t2,097\t$\t2,690\t$\t5,452\tNet income (loss) per share attributable to Gilead common stockholders - basic\t$\t(\t0.92\t)\t$\t1.62\t$\t2.12\t$\t4.19\tShares used in per share calculation - basic\t1,267\t1,296\t1,271\t1,302\tNet income (loss) per share attributable to Gilead common stockholders - diluted\t$\t(\t0.92\t)\t$\t1.60",
            "Consolidated Balance Sheets. The remaining financial instruments are reported in our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.\tThe following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):\tSeptember 30, 2019\tDecember 31, 2018\tLevel 1\tLevel 2\tLevel 3\tTotal\tLevel 1\tLevel 2\tLevel 3\tTotal\tAssets:\tAvailable-for-sale debt securities:\tU.S. treasury securities\t$\t2,860\t$\t \t$\t \t$\t2,860\t$\t3,969\t$\t \t$\t \t$\t3,969\tCertificates of deposit\t \t4,152\t \t4,152\t \t4,361\t \t4,361\tU.S. government agencies securities\t \t1,145\t \t1,145\t \t938\t \t938\tNon-U.S. government securities\t \t192\t \t192\t \t305\t \t305\tCorporate debt securities\t \t10,474\t \t10,474\t \t13,067\t \t13,067\tResidential mortgage and asset-backed securities\t \t230\t \t230\t \t1,524\t \t1,524\tEquity securities:\tEquity investment in Galapagos\t2,082\t \t \t2,082\t622\t \t \t622\tMoney market funds\t3,599\t \t \t3,599\t5,305\t \t \t5,305\tPublicly traded equity securities\t287\t9\t \t296\t259\t \t \t259\tDeferred compensation plan\t159\t \t \t159\t124\t \t \t124\tForeign currency derivative contracts\t \t80\t \t80\t \t78\t \t78\tTotal\t$\t8,987\t$\t16,282\t$\t \t$\t25,269\t$\t10,279\t$\t20,273\t$\t \t$\t30,552\tLiabilities:\tDeferred compensation plan\t$\t159\t$\t \t$\t \t$\t159\t$\t124\t$\t \t$\t \t$\t124\tForeign currency derivative contracts\t \t1\t \t1\t \t1\t \t1\tTotal\t$\t159\t$\t1\t$\t \t$\t160\t$\t124\t$\t1\t$\t \t$\t125\tChanges in the fair value of equity securities resulted in net unrealized gains of\t$\t58\tmillion\tand\t$\t312\tmillion\tfor the\tthree and nine months ended September 30, 2019\t, respectively, and net unrealized gains of\t$\t168\tmillion\tand\t$\t149\tmillion\tfor the\tthree\t12\tand nine months ended September 30, 2018\t, respectively, which were included in Other income (expense), net on our Condensed Consolidated Statements of Operations. Investments in equity securities without readily determinable fair values were not material for the periods presented.\tThe following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets (in millions):\tSeptember 30, 2019\tDecember 31, 2018\tPrepaid and other current assets\t$\t \t$\t622\tOther long-term assets\t2,082\t \tTotal\t$\t2,082\t$\t622\tSee Note 6. Collaborative and Other Arrangements for additional information on the classification of our equity investment in Galapagos.\tThe following table summarizes the classification of our other equity securities in our Condensed Consolidated Balance Sheets (in millions):\tSeptember 30, 2019\tDecember 31, 2018\tCash and cash equivalents\t$\t3,599\t$\t5,305\tPrepaid and other current assets\t292\t241\tOther long-term assets\t163\t142\tTotal\t$\t4,054\t$\t5,688\tOur available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Condensed Consolidated Balance Sheets. See Note\t4\t. Available-for-Sale Debt S",
            "Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.\tThe following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):\tSeptember 30, 2019\tDecember 31, 2018\tLevel 1\tLevel 2\tLevel 3\tTotal\tLevel 1\tLevel 2\tLevel 3\tTotal\tAssets:\tAvailable-for-sale debt securities:\tU.S. treasury securities\t$\t2,860\t$\t \t$\t \t$\t2,860\t$\t3,969\t$\t \t$\t \t$\t3,969\tCertificates of deposit\t \t4,152\t \t4,152\t \t4,361\t \t4,361\tU.S. government agencies securities\t \t1,145\t \t1,145\t \t938\t \t938\tNon-U.S. government securities\t \t192\t \t192\t \t305\t \t305\tCorporate debt securities\t \t10,474\t \t10,474\t \t13,067\t \t13,067\tResidential mortgage and asset-backed securities\t \t230\t \t230\t \t1,524\t \t1,524\tEquity securities:\tEquity investment in Galapagos\t2,082\t \t \t2,082\t622\t \t \t622\tMoney market funds\t3,599\t \t \t3,599\t5,305\t \t \t5,305\tPublicly traded equity securities\t287\t9\t \t296\t259\t \t \t259\tDeferred compensation plan\t159\t \t \t159\t124\t \t \t124\tForeign currency derivative contracts\t \t80\t \t80\t \t78\t \t78\tTotal\t$\t8,987\t$\t16,282\t$\t \t$\t25,269\t$\t10,279\t$\t20,273\t$\t \t$\t30,552\tLiabilities:\tDeferred compensation plan\t$\t159\t$\t \t$\t \t$\t159\t$\t124\t$\t \t$\t \t$\t124\tForeign currency derivative contracts\t \t1\t \t1\t \t1\t \t1\tTotal\t$\t159\t$\t1\t$\t \t$\t160\t$\t124\t$\t1\t$\t \t$\t125\tChanges in the fair value of equity securities resulted in net unrealized gains of\t$\t58\tmillion\tand\t$\t312\tmillion\tfor the\tthree and nine months ended September 30, 2019\t, respectively, and net unrealized gains of\t$\t168\tmillion\tand\t$\t149\tmillion\tfor the\tthree\t12\tand nine months ended September 30, 2018\t, respectively, which were included in Other income (expense), net on our Condensed Consolidated Statements of Operations. Investments in equity securities without readily determinable fair values were not material for the periods presented.\tThe following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets (in millions):\tSeptember 30, 2019\tDecember 31, 2018\tPrepaid and other current assets\t$\t \t$\t622\tOther long-term assets\t2,082\t \tTotal\t$\t2,082\t$\t622\tSee Note 6. Collaborative and Other Arrangements for additional information on the classification of our equity investment in Galapagos.\tThe following table summarizes the classification of our other equity securities in our Condensed Consolidated Balance Sheets (in millions):\tSeptember 30, 2019\tDecember 31, 2018\tCash and cash equivalents\t$\t3,599\t$\t5,305\tPrepaid and other current assets\t292\t241\tOther long-term assets\t163\t142\tTotal\t$\t4,054\t$\t5,688\tOur available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Condensed Consolidated Balance Sheets. See Note\t4\t. Available-for-Sale Debt Securities for additional information.\tLevel 2 Inputs\tWe estimate the fair values of Level 2 ins",
            "Consolidated Balance Sheets (in millions):\tSeptember 30, 2019\tDecember 31, 2018\tCash and cash equivalents\t$\t3,476\t$\t10,592\tShort-term marketable securities\t13,382\t12,149\tLong-term marketable securities\t2,195\t1,423\tTotal\t$\t19,053\t$\t24,164\tThe following table summarizes our available-for-sale debt securities by contractual maturity (in millions):\tSeptember 30, 2019\tAmortized Cost\tFair Value\tWithin one year\t$\t16,858\t$\t16,859\tAfter one year through five years\t2,166\t2,166\tAfter five years through ten years\t14\t14\tAfter ten years\t14\t14\tTotal\t$\t19,052\t$\t19,053\t14\tThe following table summarizes our available-for-sale debt securities that were in a continuous unrealized loss position, but were not deemed to be other-than-temporarily impaired (in millions):\tLess Than 12 Months\t12 Months or Greater\tTotal\tGross\tUnrealized\tLosses\tEstimated\tFair Value\tGross\tUnrealized\tLosses\tEstimated\tFair Value\tGross\tUnrealized\tLosses\tEstimated\tFair Value\tSeptember 30, 2019\tU.S. treasury securities\t$\t(\t1\t)\t$\t1,339\t$\t \t$\t96\t$\t(\t1\t)\t$\t1,435\tU.S. government agencies securities\t \t902\t \t30\t \t932\tNon-U.S. government securities\t \t25\t \t \t \t25\tCorporate debt securities\t(\t1\t)\t1,541\t \t297\t(\t1\t)\t1,838\tResidential mortgage and asset-backed securities\t \t10\t(\t1\t)\t171\t(\t1\t)\t181\tTotal\t$\t(\t2\t)\t$\t3,817\t$\t(\t1\t)\t$\t594\t$\t(\t3\t)\t$\t4,411\tDecember 31, 2018\tU.S. treasury securities\t$\t \t$\t896\t$\t(\t9\t)\t$\t1,383\t$\t(\t9\t)\t$\t2,279\tU.S. government agencies securities\t \t30\t(\t5\t)\t553\t(\t5\t)\t583\tNon-U.S. government securities\t \t86\t(\t2\t)\t192\t(\t2\t)\t278\tCorporate debt securities\t(\t1\t)\t1,600\t(\t28\t)\t4,204\t(\t29\t)\t5,804\tResidential mortgage and asset-backed securities\t \t192\t(\t8\t)\t1,186\t(\t8\t)\t1,378\tTotal\t$\t(\t1\t)\t$\t2,804\t$\t(\t52\t)\t$\t7,518\t$\t(\t53\t)\t$\t10,322\tWe held a total of\t355\tand\t1,348\tpositions, which were in an unrealized loss position, as of\tSeptember 30, 2019\tand\tDecember 31, 2018\t, respectively.\tBased on our review of these securities, we believe we had\tno\tother-than-temporary impairments as of\tSeptember 30, 2019\tand\tDecember 31, 2018\t, because we do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and losses were not material for the\tthree and nine months ended September 30, 2019\tand\t2018\t.\t5\t.\tDERIVATIVE FINANCIAL INSTRUMENTS\tOur operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a resul",
            "Consolidated Balance Sheets (in millions):\tSeptember 30, 2019\tAsset Derivatives\tLiability Derivatives\tClassification\tFair Value\tClassification\tFair Value\tDerivatives designated as hedges:\tForeign currency exchange contracts\tOther current assets\t$\t75\tOther accrued liabilities\t$\t(\t1\t)\tForeign currency exchange contracts\tOther long-term assets\t5\tOther long-term obligations\t \tTotal derivatives designated as hedges\t80\t(\t1\t)\tDerivatives not designated as hedges:\tForeign currency exchange contracts\tOther current assets\t \tOther accrued liabilities\t \tTotal derivatives not designated as hedges\t \t \tTotal derivatives\t$\t80\t$\t(\t1\t)\tDecember 31, 2018\tAsset Derivatives\tLiability Derivatives\tClassification\tFair Value\tClassification\tFair Value\tDerivatives designated as hedges:\tForeign currency exchange contracts\tOther current assets\t$\t73\tOther accrued liabilities\t$\t(\t1\t)\tForeign currency exchange contracts\tOther long-term assets\t5\tOther long-term obligations\t \tTotal derivatives designated as hedges\t78\t(\t1\t)\tDerivatives not designated as hedges:\tForeign currency exchange contracts\tOther current assets\t \tOther accrued liabilities\t \tTotal derivatives not designated as hedges\t \t \tTotal derivatives\t$\t78\t$\t(\t1\t)\tThe following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements (in millions):\tThree Months Ended\tNine Months Ended\tSeptember 30,\tSeptember 30,\t2019\t2018\t2019\t2018\tDerivatives designated as hedges:\tGains (losses) recognized in AOCI\t$\t69\t$\t(\t6\t)\t$\t98\t$\t52\tGains (losses) reclassified from AOCI into product sales\t31\t(\t8\t)\t96\t(\t101\t)\tDerivatives not designated as hedges:\tGains recognized in Other income (expense), net\t$\t40\t$\t15\t$\t29\t$\t11\t16\tThe following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets (in millions):\tGross Amounts Not Offset\ton our Condensed\tConsolidated Balance Sheets\tDescription\tGross Amounts\tof Recognized\tAssets/Liabilities\tGross Amounts\tOffset on our\tCondensed\tConsolidated\tBalance Sheets\tAmounts of Assets/Liabilities Presented\ton our Condensed Consolidated\tBalance Sheets\tDerivative\tFinancial\tInstruments\tCash Collateral\tReceived/\tPledged\tNet Amount\t(Legal Offset)\tAs of September 30, 2019\tDerivative assets\t$\t80\t$\t \t$\t80\t$\t(\t1\t)\t$\t \t$\t79\tDerivative liabilities\t(\t1\t)\t \t(\t1\t)\t1\t \t \tAs of December 31, 2018\tDerivative assets\t$\t78\t$\t \t$\t78\t$\t(\t1\t)\t$\t \t$\t77\tDerivative liabilities\t(\t1\t)\t \t(\t1\t)\t1\t \t \tFrom time to time, we may discontinue cash flow hedges and, as a result, record related amounts in\tOther income (expense), net\ton our Condensed Consolidated Statements of Operations. There was\tno\tdiscontinuance of cash flow hedges for the\tthree and nine months ended September 30, 2019\tand\t2018\t.\t6\t.\tCOLLABORATIVE AND OTHER ARRANGEMENTS\tWe enter into collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. Thes"
        ],
        "timestamp": "2025-01-21_09-38-40"
    }
}